News
Eli Lilly says new GLP-1 weight loss pill could reach market in 2026
Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill for FDA approval by the end of the year. The pill does not produce the same amount of weight loss as injections,
1hon MSN
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...
Note that some links may require registration or subscription. The Trump administration is set to announce a proposed rule ...
Eli Lilly (LLY) raised its full-year forecast after beating second quarter expectations, but shares slipped as its ...
Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.
Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback